<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="924">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05149118</url>
  </required_header>
  <id_info>
    <org_study_id>B-1811-507-005</org_study_id>
    <nct_id>NCT05149118</nct_id>
  </id_info>
  <brief_title>Effect of PDRN in Post-operative Scars</brief_title>
  <official_title>Early Postoperative Injections of Polydeoxyribonucleotide Prevents Hypertrophic Scarring After Thyroidectomy: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aimed to evaluate the efficacy of PDRN administration in early wound&#xD;
      healing phase on prevention of post-operative scars after open thyroidectomy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Actual">October 31, 2021</completion_date>
  <primary_completion_date type="Actual">October 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>modified Vancouver Scar Scale (0 normal skin~15 worst) at the 3-month follow-up</measure>
    <time_frame>at 3 months</time_frame>
    <description>modified Vancouver Scar Scale (0 normal skin~15 worst)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective symptoms at the 3-month follow-up</measure>
    <time_frame>at 3 months</time_frame>
    <description>Pain and itching were assessed using a visual analog scale (VAS) ranged from 0 (no) to 10 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythema and pigmentation at the 3-month follow-up</measure>
    <time_frame>at 3 months</time_frame>
    <description>Erythema Index (EI, arbitrary unit) and the Melanin Index (MI,arbitrary unit)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scar Height (mm) at the 3-month follow-up</measure>
    <time_frame>at 3 months</time_frame>
    <description>3D images of the scars were acquired with an Antera 3D® camera (Miravex Limited, Dublin, Ireland)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Scar</condition>
  <arm_group>
    <arm_group_label>PDRN injected group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants in treatment group had received two consecutive injections of PDRN one day and two days after the surgery. A total 1mL of PDRN was injected along the suture line at distance of 1cm in each session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The participants in control group were left untreated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Polydeoxyribonucleotide (PDRN)</intervention_name>
    <description>A total 1mL of PDRN was injected along the suture line at distance of 1cm in one day and two days after the surgery.</description>
    <arm_group_label>PDRN injected group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        • Participants who underwent open thyroidectomy between February 2019 and March 2021 at the&#xD;
        Thyroid Cancer Center, Department of otorhinolaryngology, Seoul National University Bundang&#xD;
        Hospital&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age younger than 20 years or older than 60 years&#xD;
&#xD;
          -  history of keloid development&#xD;
&#xD;
          -  requirement for modified radical neck dissection&#xD;
&#xD;
          -  previous neck surgery&#xD;
&#xD;
          -  current pregnancy or breast feeding&#xD;
&#xD;
          -  allergy to PDRN&#xD;
&#xD;
          -  taking medications that may affect inflammation and would healing such as&#xD;
             isotretinoin, anti-cancer drugs, high dose corticosteroids, and anticoagulants&#xD;
&#xD;
          -  uncontrolled medical diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jung Won Shin, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>November 25, 2021</last_update_submitted>
  <last_update_submitted_qc>November 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Jung-Won Shin</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

